<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245869</url>
  </required_header>
  <id_info>
    <org_study_id>CT03-FD/COR</org_study_id>
    <nct_id>NCT00245869</nct_id>
  </id_info>
  <brief_title>Ultrasound and Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response</brief_title>
  <official_title>Contrast-Enhanced Ultrasound and Neoadjuvant Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <brief_summary>
    <textblock>
      This study intends to assess the ability of contrast-enhanced ultrasound to make the efficacy
      of chemotherapy in breast cancer precise.

      This real-time noninvasive and feasible imaging technique allows us, the investigators at
      University Hospital Tours, to evaluate early vascular changes of breast tumors during
      treatment. These vascular changes may precede long-term tumoral regression. Imaging of
      primary breast lesions may be of value in the prediction of late treatment response.

      An ultrasound will be performed before the initiation, and after the second and the last dose
      of chemotherapy.

      To investigate the changes occurring in the vascularization of tumors, we will use an
      intravascular ultrasound contrast agent SonoVue (sulphur hexafluoride microbubbles).

      This agent is a microbubbles preparation that is stable, resistant to pressure, and
      specifically designed to be used as a contrast agent for ultrasound imaging of angiogenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to evaluate the early vascular changes of the tumor during
      neoadjuvant chemotherapy compared to the clinical or MRI or histological response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>February 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>From contrast-enhanced ultrasound: Enhancement parameters derived from time-intensity curves</measure>
  </primary_outcome>
  <enrollment>30</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast-enhanced Ultrasound</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast tumor (size equal to or greater than 3 cm.). Patients with diagnosis of benign
             breast tumor based on biopsy will be excluded from the study after the first
             ultrasound examination.

          -  Neoadjuvant chemotherapy is programmed when an epithelial carcinoma is diagnosed by
             histology.

          -  Performance status = 0, 1 or 2

          -  No previous surgery or local radiotherapy

        Exclusion Criteria:

          -  Psychiatric disorders

          -  Vital threat due to other disease

          -  Vital prognosis &lt; 3 months

          -  Biopsy of the lesion performed within 1 month before the ultrasonography

          -  Patient known to have a coronary syndrome

          -  Unstable angina and myocardial infarction

          -  Acute cardiac failure, Class III/IV cardiac failure

          -  Several arrhythmias

          -  Acute endocarditis

          -  Prosthetic valves
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Tranquart, PR</last_name>
    <role>Study Director</role>
    <affiliation>Centre d'Innovation Technologique - CHRU Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine LABBE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRLCC René Gauducheau 44805 ST HERBLAIN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A. Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer. 2005;12(1):45-51.</citation>
    <PMID>15657523</PMID>
  </reference>
  <reference>
    <citation>Watermann D, Madjar H, Sauerbrei W, Hirt V, Prömpeler H, Stickeler E. Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. Oncol Rep. 2004 Apr;11(4):905-10.</citation>
    <PMID>15010893</PMID>
  </reference>
  <reference>
    <citation>Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995 Jan;1(1):27-31. Review.</citation>
    <PMID>7584949</PMID>
  </reference>
  <reference>
    <citation>Hansen S, Grabau DA, Rose C, Bak M, Sørensen FB. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest. 1998 Dec;78(12):1563-73.</citation>
    <PMID>9881956</PMID>
  </reference>
  <reference>
    <citation>Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res. 2000 Jan;6(1):139-46.</citation>
    <PMID>10656442</PMID>
  </reference>
  <reference>
    <citation>Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000 Apr;18(8):1676-88.</citation>
    <PMID>10764428</PMID>
  </reference>
  <reference>
    <citation>Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H, Schwaiger M. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000 Apr;18(8):1689-95.</citation>
    <PMID>10764429</PMID>
  </reference>
  <reference>
    <citation>Denis F, Bougnoux P, Paon L, le Floch O, Tranquart F. Radiosensitivity of rat mammary tumors correlates with early vessel changes assessed by power Doppler sonography. J Ultrasound Med. 2003 Sep;22(9):921-9.</citation>
    <PMID>14510263</PMID>
  </reference>
  <reference>
    <citation>Denis F, Colas S, Chami L, Louisot P, Le Floch O, Tranquart F, Bougnoux P. Changes in tumor vascularization after irradiation, anthracyclin, or antiangiogenic treatment in nitrosomethyl ureas-induced rat mammary tumors. Clin Cancer Res. 2003 Oct 1;9(12):4546-52.</citation>
    <PMID>14555529</PMID>
  </reference>
  <reference>
    <citation>Kook SH, Kwag HJ. Value of contrast-enhanced power Doppler sonography using a microbubble echo-enhancing agent in evaluation of small breast lesions. J Clin Ultrasound. 2003 Jun;31(5):227-38.</citation>
    <PMID>12767017</PMID>
  </reference>
  <reference>
    <citation>Solesvik OV, Rofstad EK, Brustad T. Vascular changes in a human malignant melanoma xenograft following single-dose irradiation. Radiat Res. 1984 Apr;98(1):115-28.</citation>
    <PMID>6718687</PMID>
  </reference>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>February 19, 2007</last_update_submitted>
  <last_update_submitted_qc>February 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2007</last_update_posted>
  <keyword>Contrast-enhanced Ultrasound</keyword>
  <keyword>Ultrasound Contrast agents, microbubbles</keyword>
  <keyword>breast cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>vascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

